Conversely, while LDHA demonstrates robust antitumor potency in glioma models, the absence of formal human trials currently designates it as a medium-to-long-term ‘high-risk, high-reward’ target, requiring validation of safety and efficacy through rigorously designed early-phase exploratory studies. This evidence concerns the gene LDHA and glioma.